IntrinsicIntrinsic
← All summaries

Erasca, Inc.

ERAS
Financials & Chart →

Business Summary

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's mission is to "erase cancer" by targeting molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, which collectively affect over five million new patients globally each year . Erasca was co-founded by pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens to comprehensively shut down the RAS/MAPK pathway .

The company's core business model revolves around the discovery, development, and potential commercialization of precision oncology medicines. Revenue generation is currently not established, as the company has no products approved for sale and has incurred significant operating losses since its inception . Erasca generates income through upfront payments and potential milestone payments from licensing agreements, such as the $12.5 million upfront cash payment from Joyo and $10.0 million from Medshine , . The primary customer segments, if products are approved, would be cancer patients with RAS/MAPK pathway-driven tumors. The company emphasizes a holistic, data-driven, portfolio-wide clinical development effort, pursuing three therapeutic strategies: targeting upstream and downstream MAPK pathway nodes, directly targeting RAS, and targeting escape routes that emerge in response to treatment .

Erasca's pipeline includes two clinical-stage programs and one discovery-stage program. The RAS franchise comprises ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS small molecule inhibitor, both of which had their Investigational New Drug (IND) applications cleared by the US Food and Drug Administration (FDA) in May 2025 . ERAS-0015 is being evaluated in the AURORAS-1 Phase 1 trial and the JYP0015M101 clinical trial in China, sponsored by Joyo . ERAS-4001 is being assessed in the BOREALIS-1 Phase 1 trial . The company believes ERAS-0015 has the potential to address approximately 2.7 million patients diagnosed annually worldwide with RAS-mutant tumors, including over 2.2 million patients with KRAS-mutant tumors that ERAS-4001 could also address . The third program, ERAS-12, is a discovery-stage investigational EGFR D2/D3 biparatopic antibody, for which a lead candidate has been identified . This biologic is designed to inhibit EGFR through multiple mechanisms, including binding to both domain II and domain III of EGFR, and aims to exploit the innate immune system to induce tumor cell apoptosis .

For the fiscal year ended December 31, 2025, Erasca reported net losses of $124.5 million . As of December 31, 2025, the company had an accumulated deficit of $892.2 million . No revenue figures, gross profit, gross margin, operating income, operating margin, basic and diluted EPS, free cash flow, cash and equivalents, total debt, or net debt were explicitly provided for the reported fiscal period.

Comparing year-over-year, the net loss for the year ended December 31, 2025, was $124.5 million, an improvement from the net loss of $161.7 million for the year ended December 31, 2024 . This represents a reduction in net loss of $37.2 million. No other specific year-over-year comparisons for revenue growth by segment, margin expansion or contraction, or notable shifts in business mix were provided in the filing.

Significant operational developments during the period include the in-licensing of the RAS-targeting franchise (ERAS-0015 and ERAS-4001) in May 2024 . The INDs for both ERAS-0015 and ERAS-4001 were cleared by the FDA in May 2025 . In January 2026, Erasca provided an update on ERAS-0015's initial clinical progress, noting faster-than-anticipated dose escalation in the AURORAS-1 Phase 1 trial, ongoing confirmed and unconfirmed responses in multiple patients at doses as low as 8 mg once daily (QD), and favorable safety and tolerability with no dose-limiting toxicities . Subsequent to the cutoff date, patients were dosed at 40 mg QD . The company also made a strategic decision to stop development of naporafenib, terminating its exclusive license agreement with Novartis Pharma AG in March 2026, effective June 3, 2026 . Similarly, Erasca deprioritized the ERAS-007 program in May 2024 and terminated the Asana License Agreement in September 2025, effective November 8, 2025 . The ERAS-601 program was also deprioritized in November 2023, and the NiKang License Agreement was terminated in September 2025, effective October 9, 2025 . The Katmai License Agreement for ERAS-801 was terminated in April 2025, effective April 1, 2025 . In March 2026, Erasca exercised its option to expand the territory of the Joyo License Agreement to include mainland China, Hong Kong, and Macau, making a corresponding $150.0 million payment .

Business Outlook

Management anticipates a Phase 1 monotherapy data readout from the AURORAS-1 and JYP0015M101 trials for ERAS-0015 in the first half of 2026 . Following this, the initiation of monotherapy expansion cohorts and combination dose escalation cohorts as part of the AURORAS-1 trial is expected in the second half of 2026, with associated data readouts planned for 2027 . For ERAS-4001, a Phase 1 monotherapy data readout from the BOREALIS-1 trial is anticipated in the second half of 2026 , with the initiation of monotherapy expansion cohorts and combination dose escalation cohorts expected in 2027 . The company believes its existing cash, cash equivalents, and marketable securities, combined with the net proceeds of $242.7 million from the January 2026 public offering of 25,875,000 shares at $10.00 per share , less the $150.0 million payment to Joyo in March 2026 , will fund operations into the second half of 2028 .

A major growth area for Erasca is the advancement of its RAS-targeting franchise, ERAS-0015 and ERAS-4001. ERAS-0015, a pan-RAS molecular glue, is being developed for RAS-mutated solid tumors, with preclinical data showing 8-21 times higher binding affinity to cyclophilin A and approximately 5 times more potent RAS inhibition in cell-based assays compared to the most advanced pan-RAS molecular glue in development . This higher potency and favorable ADME/PK properties are expected to enable lower dosing, potentially leading to linear PK, better GI tolerability, and an improved therapeutic window . ERAS-0015 has demonstrated comparable to greater in vivo antitumor activity at doses approximately one-tenth to one-eighth of the comparator . The company is pursuing a clinical development strategy to address high unmet medical needs in tumor types such as colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC) .

Another significant growth area is ERAS-4001, a pan-KRAS inhibitor, intended for KRAS-mutated solid tumors. Preclinical data indicate good activity against KRAS G12X mutations and KRAS wildtype amplifications, with no activity against HRAS or NRAS wildtype proteins, which is believed to offer a wider therapeutic window . ERAS-4001 potently inhibited KRAS in both GTP- and GDP-bound states with single-digit nanomolar IC50s in biochemical assays . In vivo, it showed tumor regression in multiple models as monotherapy and achieved complete disappearance of tumors in combination with an anti-PD-1 antibody in a KPC KRAS G12D CDX model, suggesting immunologic antitumor memory . The company plans to move swiftly into strategic combinations while characterizing monotherapy activity and combination potential for both ERAS-0015 and ERAS-4001, capitalizing on their complementary mechanisms of action .

Operationally, Erasca is focused on advancing its differentiated RAS-targeting franchise, which led to the strategic decision to discontinue development of naporafenib, ERAS-007, ERAS-601, and ERAS-801 to prioritize resources . The company intends to maintain exclusive worldwide development and commercialization rights for its product candidates and, if approved, build a focused sales and marketing organization in the United States and potentially Europe . For other regions, Erasca intends to explore commercialization partnerships . The company currently has no sales, marketing, or commercial product distribution capabilities and plans to build this infrastructure over time .

Regarding capital allocation, Erasca anticipates that its existing capital, combined with the net proceeds from the January 2026 offering, will fund operations into the second half of 2028 . The company expects its expenses to increase as it conducts ongoing and future clinical trials and preclinical studies, seeks regulatory approval, and potentially commercializes product candidates . Milestone payments to licensors for ERAS-0015 and ERAS-4001 are also anticipated . Erasca may seek additional funding through equity or debt financings or collaborations, licenses, and other arrangements . In August 2025, the company entered into an Amended and Restated Open Market Sale Agreement to sell up to $200 million of common stock .

Structural headwinds and execution risks management explicitly flagged include the capital-intensive nature of biopharmaceutical development and the need for substantial additional funding, with no committed external source of funds . The company's estimates for capital sufficiency are based on assumptions that may prove incorrect, potentially requiring additional funds sooner than expected . Raising additional capital may dilute ownership, restrict operations, or require relinquishing rights to technologies or product candidates . The company's portfolio of investments may be subject to market, interest, and credit risk, which could reduce their value and impair funding ability . The scientific approach to product candidate discovery and development is unproven, and there is no guarantee of developing commercially valuable products or that competing approaches will not limit their value . Clinical and preclinical development is lengthy, expensive, and uncertain, with results not necessarily predictive of future outcomes . Difficulties in patient enrollment for clinical trials could delay or adversely affect development activities . Use of product candidates could be associated with side effects or safety risks, potentially delaying or precluding approval . The company relies on third parties for clinical trials and manufacturing, increasing the risk of insufficient quantities or delays . Geopolitical and economic events, including inflation, interest rate changes, and financial institution instability, could adversely affect financial markets and the company's business .

Risk Factors

Erasca faces significant risks, including its limited operating history and consistent operating losses, with a net loss of $124.5 million in 2025 and an accumulated deficit of $892.2 million as of December 31, 2025 , . The company will require substantial additional capital to finance operations, and failure to obtain it could delay or terminate development programs . Clinical and preclinical development is lengthy, expensive, and uncertain, with no guarantee of favorable results or regulatory approval . Product candidates may cause side effects or adverse events, potentially delaying or precluding approval . Reliance on third parties for clinical trials and manufacturing increases the risk of delays or insufficient supplies . The company faces significant competition from larger, better-funded entities developing cancer treatments, including those targeting the RAS/MAPK pathway . Intellectual property protection is crucial but uncertain, with risks of patents being found invalid or unenforceable . The trading price of common stock is highly volatile, and sales by existing stockholders could cause price declines . The company is subject to evolving US federal, state, and foreign healthcare laws and regulations, including anti-kickback, fraud and abuse, and data privacy laws like HIPAA and the EU GDPR, with non-compliance potentially leading to significant fines and penalties . The recently enacted US BIOSECURE Act in December 2025 could restrict the ability to purchase services or products from, or collaborate with, "biotechnology companies of concern" if any current or future suppliers are designated as such, potentially impacting supply chains and operations . The One Big Beautiful Bill Act, enacted in July 2025, imposes significant reductions in Medicaid funding, which could decrease enrollment and covered services, adversely affecting future product sales . The current Presidential administration's proposed policies to reduce drug costs, including potential tariffs on manufacturers not adopting most favored nation pricing, could negatively impact the pharmaceutical industry and the company's revenues .

Management Priorities

Management's message to shareholders emphasizes a singular mission to "erase cancer" by targeting RAS/MAPK pathway-driven cancers, a disease affecting over five million new patients globally each year . They highlight a holistic, data-driven approach, combining internal development with global in-licensing and acquisition strategies to build a modality-agnostic pipeline. Strategic priorities include relentlessly focusing on patients and society, developing novel single and combination regimens to comprehensively shut down the RAS/MAPK pathway, advancing the current clinical-stage pipeline (ERAS-0015 and ERAS-4001), internally developing and externally sourcing disruptive programs, and leading the next revolution in precision oncology . Management anticipates a Phase 1 monotherapy data readout for ERAS-0015 in the first half of 2026 , and for ERAS-4001 in the second half of 2026 . They also project that existing cash, cash equivalents, and marketable securities, combined with the net proceeds of $242.7 million from the January 2026 public offering , less the $150.0 million payment to Joyo in March 2026 , will fund operations into the second half of 2028 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  4. [4] Item 1, Business — Guangzhou Joyo
  5. [5] Item 1, Business — Medshine
  6. [6] Item 1, Business — Overview
  7. [7] Item 1, Business — RAS Franchise: ERAS-0015 pan-RAS molecular glue and ERAS-4001 pan-KRAS small molecule inhibitor
  8. [8] Item 1, Business — Initial clinical development strategy for ERAS-0015
  9. [9] Item 1, Business — Initial clinical development strategy for ERAS-4001
  10. [10] Item 1, Business — Overview
  11. [11] Item 1, Business — Our next program is ERAS-12, our investigational EGFR D2/D3 biparatopic antibody (bpAb)
  12. [12] Item 1, Business — ERAS-12: our EGFR D2/D3 biparatopic antibody program
  13. [13] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  14. [14] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  15. [15] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  16. [16] Item 1, Business — Overview
  17. [17] Item 1, Business — RAS Franchise: ERAS-0015 pan-RAS molecular glue and ERAS-4001 pan-KRAS small molecule inhibitor
  18. [18] Item 1, Business — Early clinical progress of ERAS-0015
  19. [19] Item 1, Business — Early clinical progress of ERAS-0015
  20. [20] Item 1, Business — Novartis
  21. [21] Item 1, Business — Asana BioSciences
  22. [22] Item 1, Business — NiKang Therapeutics, Inc.
  23. [23] Item 1, Business — Katmai Pharmaceuticals
  24. [24] Item 1, Business — Guangzhou Joyo
  25. [25] Item 1, Business — Initial clinical development strategy for ERAS-0015
  26. [26] Item 1, Business — Initial clinical development strategy for ERAS-0015
  27. [27] Item 1, Business — Initial clinical development strategy for ERAS-4001
  28. [28] Item 1, Business — Initial clinical development strategy for ERAS-4001
  29. [29] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  30. [30] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  31. [31] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  32. [32] Item 1, Business — Biophysical characterization of ERAS-0015
  33. [33] Item 1, Business — ERAS-0015: our pan-RAS molecular glue
  34. [34] Item 1, Business — Preclinical efficacy of ERAS-0015
  35. [35] Item 1, Business — RAS Franchise: ERAS-0015 pan-RAS molecular glue and ERAS-4001 pan-KRAS small molecule inhibitor
  36. [36] Item 1, Business — Biophysical characterization and preclinical potency of ERAS-4001
  37. [37] Item 1, Business — Biophysical characterization and preclinical potency of ERAS-4001
  38. [38] Item 1, Business — Preclinical activity of ERAS-4001
  39. [39] Item 1, Business — RAS Franchise: ERAS-0015 pan-RAS molecular glue and ERAS-4001 pan-KRAS small molecule inhibitor
  40. [40] Item 1, Business — Overview
  41. [41] Item 1, Business — Commercialization
  42. [42] Item 1, Business — Commercialization
  43. [43] Item 1, Business — Commercialization
  44. [44] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  45. [45] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  46. [46] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  47. [47] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  48. [48] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  49. [49] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  50. [50] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  51. [51] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  52. [52] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  53. [53] Item 1A, Risk Factors — Our scientific approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing approaches will limit the commercial value of our product candidates.
  54. [54] Item 1A, Risk Factors — Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.
  55. [55] Item 1A, Risk Factors — We may find it difficult to enroll patients in our clinical trials.
  56. [56] Item 1A, Risk Factors — Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.
  57. [57] Item 1A, Risk Factors — We rely on third parties to conduct our clinical trials and preclinical studies.
  58. [58] Item 1A, Risk Factors — Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.
  59. [59] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  60. [60] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  61. [61] Item 1A, Risk Factors — We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
  62. [62] Item 1A, Risk Factors — Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.
  63. [63] Item 1A, Risk Factors — Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.
  64. [64] Item 1A, Risk Factors — We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future.
  65. [65] Item 1A, Risk Factors — We face significant competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.
  66. [66] Item 1A, Risk Factors — If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.
  67. [67] Item 1A, Risk Factors — The trading price of the shares of our common stock has been, and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses.
  68. [68] Item 1A, Risk Factors — We are subject to various US federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.
  69. [69] Item 1A, Risk Factors — Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  70. [70] Item 1A, Risk Factors — Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.
  71. [71] Item 1A, Risk Factors — Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.
  72. [72] Item 1, Business — Overview
  73. [73] Item 1, Business — Our corporate strategies to erase cancer
  74. [74] Item 1, Business — Initial clinical development strategy for ERAS-0015
  75. [75] Item 1, Business — Initial clinical development strategy for ERAS-4001
  76. [76] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  77. [77] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital
  78. [78] Item 1A, Risk Factors — Risks related to our limited operating history, financial position and need for additional capital

Analysis on 5/21/2026